

EXHIBIT A

Award Date	Voucher Type	Company	Drug	Disease	Status	Drug Redeemed for	Disease Redeemed Drug Treats	Sale Value	Sale Date	Purchaser
Apr 2009	Tropical Disease	Novartis AG	Coartem (artemether/ lumefantrine)	Malaria	Used – redeemed Feb 2011 to unsuccessful results	ILARIS sBLA	Gout	N/A	N/A	N/A
Sept 2012	Tropical Disease	Janssen Pharmaceuticals, Inc.	Sirturo (bedaquiline)	Tuberculosis	Unused	N/A	N/A	N/A	N/A	N/A
Feb 2014	Rare Pediatric Disease	BioMarin Pharmaceutical Inc.	Vimizim (elosulfase alfa)	Morquio A syndrome	Sold, then redeemed by buyers July 2015 to successful results	Praluent (alirocumab)	heterozygous familial hypercholesterolemia (HeFH)	\$67.5 mil	July 2014	Sanofi and Regeneron Pharmaceuticals, Inc.
Mar 2014	Tropical Disease	Knight Therapeutics	Impavido (miltefosine)	Leishmaniasis	Sold, then redeemed by buyers July 2015 to successful results	R/F/TAF	HIV	\$125 mil	Nov 2014	Gilead Sciences, Inc.
Mar 2015	Rare Pediatric Disease	United Therapeutics Corporation	Unituxin (dinutuximab)	High-risk neuroblastoma	Unused	N/A	N/A	\$350 mil	Aug 2015	AbbVie Inc.
Mar 2015	Rare Pediatric Disease	Asklepion Pharmaceuticals, LLC	Cholbam	Rare bile acid synthesis disorders	Transferred to Retrophin Inc. (a BDO client) under an existing agreement, Sold, then redeemed by buyers Feb 2016 to successful results	Lixilan	Type 2 Diabetes	\$245 mil	May 2015	Sanofi
Sept 2015	Rare Pediatric Disease	Wellstat Therapeutics	Xuriden	Hereditary orotic aciduria	Transferred to AstraZeneca under an existing PRV, Unused	N/A	N/A	N/A	N/A	N/A
Nov 2015	Rare Pediatric Disease	Alexion Pharmaceuticals	Strensiq (asfotase alfa)	Hypophosphatasia	Unused	N/A	N/A	N/A	N/A	N/A
Dec 2015	Rare Pediatric Disease	Alexion Pharmaceuticals	Kanuma (sebelipase alfa)	Lysosomal acid lipase (LAL) deficiency	Unused	N/A	N/A	N/A	N/A	N/A
Jun 2016	Tropical Disease	PaxVax Corporation	Vaxchora	Cholera	Unused*	N/A	N/A	N/A	N/A	N/A
Sept 2016	Rare Pediatric Disease	Sarepta Therapeutics, Inc.	Exondys 51 (eteplirsén)	Duchenne muscular dystrophy	Sold, Unused	N/A	N/A	\$125 mil	Feb 2017	Gilead Sciences, Inc.
Dec 2016	Rare Pediatric Disease	Ionis Pharmaceuticals	Spinraza (nusinersen)	Spinal muscular atrophy (SMA)	Unused	N/A	N/A	N/A	N/A	N/A
Feb 2017	Rare Pediatric Disease	Marathon Pharmaceuticals	Emflaza (deflazacort)	Duchenne muscular dystrophy	Unused	N/A	N/A	N/A	N/A	N/A

*Likely sold to Gilead for approximately \$200 mil, based on an undisclosed PRV purchase in Gilead's Q2 2016 statement, a disclosure of \$624m increase in R&D spend, less \$400m Nimbus purchase and undisclosed clinical trial progression.